Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1402 - Prognostic impact of BRAF and KRAS mutations according to the consensus molecular subtypes of colorectal cancer


09 Sep 2017


Poster display session


Targeted Therapy;  Colon and Rectal Cancer


Jørgen Smeby


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


J. Smeby1, A. Sveen1, C.H. Bergsland1, J. Bruun1, M. Merok2, S.A. Danielsen1, M. Hektoen1, M. Eknæs1, I.A. Eilertsen1, M. Grønlie Guren3, A. Nesbakken4, R.A. Lothe1

Author affiliations

  • 1 Department Of Molecular Oncology, Oslo University Hospital, 424 - Oslo/NO
  • 2 Department Of Gastroenterological Surgery, Akershus University Hospital, 1478 - Lørenskog/NO
  • 3 Department Of Oncology, Oslo University Hospital, 424 - Oslo/NO
  • 4 Department Of Gastroenterological Surgery, Oslo University Hospital, 424 - Oslo/NO


Abstract 1402


In the present study we report the distribution and prognostic impact of KRAS and BRAF mutations according to microsatellite instability (MSI) status and consensus molecular subtypes (CMS) in colorectal cancer (CRC).


A total of 1197 primary tumor samples from a consecutive series of patients treated surgically for stage I-IV CRC at Oslo University Hospital, Norway, were included in the study. Comprehensive clinical and pathological data were prospectively collected for all patients. Mutation analyses were performed for hotspots in KRAS (exon 2: codon 12 and 13, exon 3: codon 61) and BRAF (exon 15: codon 600) and MSI-status was determined. A subset of samples were analyzed for gene expression using exon-level microarrays and classified according to the CMS groups of CRC, with confident classification obtained in 317 samples. To increase the number of samples with CMS classification the analysis was supplemented with gene expression data for 514 patients in the publically available dataset GSE39582, including also MSI status, BRAF and KRAS mutation status, as well as clinical data. Gene expression signatures previously shown to be associated with BRAF and KRAS mutations, respectively, were used to evaluate differential impact of mutations on gene expression among CMS groups.


BRAFV600E and KRAS mutations are shown to have inferior relapse-free survival in MSS tumors exclusively (BRAF mut vs KRAS/BRAF wt: Hazard ratio (HR) 2,35 (1,71-3,22); p 


BRAFV600E mutations have poor prognostic value specific to MSS tumors in CMS1, while KRAS mutations are associated with adverse outcome in MSS tumors in CMS2.

Clinical trial identification

Legal entity responsible for the study

Oslo University Hospital


Norwegian Cancer Society, Research Council of Norway, Southern and Eastern Norway Regional Health Authority


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.